Abstract
The aim of the work is to analyze and systematize the literature data regarding the current state and strategic aspect of intravenous use of diclofenac for the prevention of postoperative pain, namely clinical efficacy and safety.Materials and methods. Studies were conducted using databases on the Internet: PubMed; Food and Drug Administration, European Medicines Agency. It has used retrospective, logical, research methods, content analysis.Results. Conducted clinical data analysis indicates that diclofenac sodium, when administered intravenously, has an opioid-saving effect, is effective in patients experiencing acute postoperative pain, or as part of a multimodal analgesic strategy to achieve perioperative pain control. This increases the possibility of relief of pain and promotes accelerated rehabilitation after surgery, reduces the need for opiates. The incidence of side effects with intravenous diclofenac was similar to that seen with other treatments. New opportunities of the strategic aspect of intravenous use of diclofenac is related to the use of Dyloject, Hospira Inc., USA, which has improved solubility, shorter administration time than infusion. The incidence of thrombophlebitis on treatment with Dyloject was less pronounced compared to Voltarol.Conclusions. Thus, the experience of clinical intravenous use of diclofenac sodium for the prevention of postoperative pain has confirmed its efficacy, favorable safety profile and the ability to reduce the need for opiates. The promising strategic aspect is the creation of domestic diclofenac sodium preparations for intravenous administration, which have improved solubility, shorter administration time than infusions and have no additional safety risk
Highlights
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of drugs that are widely used in clinical practice
The intravenous administration of this injectable form of diclofenac sodium is not indicated in the instructions for use in all European countries, according to the European Medicines Agency
It should be noted that the drug Voltarol, solution for injection (Novartis Pharmaceuticals UK Ltd) for the prevention of postoperative pain in the form of intravenous infusions is presented in the British National Formulary (2018–2019), containing the main provisions of the system to ensure effective and safe pharmacotherapy [8]
Summary
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of drugs that are widely used in clinical practice. About 20 % of inpatients receive NSAIDs. About 20 % of inpatients receive NSAIDs Their popularity is explained by the fact that they have antiinflammatory, analgesic and antipyretic effects and provide relief to patients with relevant symptoms (inflammation, pain, fever), which are noted in many diseases [1]. The favorable efficacy / safety ratio, as evidenced in numerous adequate clinical studies, makes it possible to consider NSAIDs – diclofenac as the drug of choice for the treatment of degenerative-dystrophic diseases of the musculoskeletal system and other conditions accompanied by pain of different localization and intensity. Diclofenac sodium was first synthesized in 1964 and since 1974 has been widely used by doctors around the world. Using a production diversification strategy, diclofenac dosage forms for topical application, tablet formulations, injection forms were developed to improve the efficacy, tolerability and convenience of the patient [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
